Evets Drugs Profile
Key Indicators
- Authorised Capital ₹ 2.00 Cr
as on 15-12-2024
- Paid Up Capital ₹ 2.00 Cr
as on 15-12-2024
- Company Age 1 Year 6 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 3.50 Cr
as on 15-12-2024
About Evets Drugs
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.00 Cr and a paid-up capital of Rs 2.00 Cr.
The company currently has active open charges totaling ₹3.50 Cr.
Saurabh Kumar, Atul Kane, Murlidhar Kanhaiyalal, and One other member serve as directors at the Company.
- CIN/LLPIN
U21002MH2023PTC404460
- Company No.
404460
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
07 Jun 2023
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Evets Drugs?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Saurabh Kumar  | Director | 07-Jun-2023 | Current |
| Atul Kane | Director | 07-Jun-2023 | Current |
| Murlidhar Kanhaiyalal | Director | 07-Jun-2023 | Current |
| Banshidhar Kanhaiyalal | Director | 07-Jun-2023 | Current |
Financial Performance of Evets Drugs.
Enhance accessibility to Evets Drugs's financial data by unlocking access to both Standalone and Consolidated balance sheets, Profit & Loss Statements, Ratios, Related Party Transactions, and additional relevant information.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Evets Drugs?
Unlock access to Evets Drugs's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
_PRIVATE_LIMITED.webp)
Acme Therapeutics (I) Private LimitedActive 23 years 9 monthsBanshidhar Kanhaiyalal is a mutual person
Sriram Healthcare Private LimitedActive 16 years 9 monthsMurlidhar Kanhaiyalal and Banshidhar Kanhaiyalal are mutual person
- Prosperity Drugs Private LimitedActive 5 years 6 months
Murlidhar Kanhaiyalal and Banshidhar Kanhaiyalal are mutual person
- Evets Packaging Private LimitedActive 7 years 10 months
Murlidhar Kanhaiyalal and Banshidhar Kanhaiyalal are mutual person
- Evets Glass & Polymer Private LimitedActive 3 years 4 months
Murlidhar Kanhaiyalal and Banshidhar Kanhaiyalal are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 08 Sep 2023 | ₹3.50 Cr | Open |
How Many Employees Work at Evets Drugs?
Unlock and access historical data on people associated with Evets Drugs, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Evets Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Evets Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
